Noticeable OTC oscillation Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a bio-technology company, engaged in the development and marketing of diagnostic tests in the fields of cancer, neurodegenerative and neuromuscular diseases in the United States.
(EMAILWIRE.COM, September 01, 2010 ) NewYork,NY - Power3 strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies.
PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices. PWRM’s stock touched the day high of $0.029 with overall traded volume of 3.12 million shares in the last trading day. It last traded at $0.03 with the no change from its previous close. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease.
PWRM’s products analyze proteins and their mutations to assess an individuals risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. Recently, Power 3 Medical Products Inc. announced that it has filed two provisional patent applications with the United States Patent and Trademark Office.
(USPTO) – one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
These two provisional patent applications, along with the additional provisional patent application recently filed by the principals of Power3 and others on the use of stem cell protein biomarkers to monitor stem cell therapy and three other recently filed provisional patent applications on Parkinson’s and Alzheimer’s disease diagnosis, disclose a vast amount of invaluable information crucial to the accurate diagnosis and treatment of neurodegenerative diseases.
PWRM focuses on the development of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases, such as amytrophic lateral sclerosis (ALS) (also known as Lou Gehrig’s disease), Alzheimer’s disease and Parkinson’s disease.
PWRM addresses clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with academic and research institutions. Power3 applies its methodologies to discover and identify protein biomarkers associated with diseases. It has developed a portfolio of products, including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer, and NuroPro, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases.
Moreover, Power3 Medical Products Inc. plans to make acquisitions. The company is looking at several potential acquisition targets in order to increase its intellectual property portfolio. The company is eyeing acquisition opportunities that could bring promising stem cell research, patents and other intellectual property assets and technologies to help its in-house product development program.
President and Chief Scientific Officer of the company, Ira Goldknopf stated that it will continue to look for acquisitions which could increase shareholder value so stay connected to know more.
Happy trading,
http://www.mybestpicksever.com
MyBestPicksEver offers stock newsletters on various stock plays of the day. MBPE offers news on top stocks, small cap penny stocks and other market movers alike. MBPE help investors in making the wise stock market investments. thus far thousands of our subscribers made huge gains using our daily penny stock alerts. join our FREE news letter Now Or Become a VIP MEMBER.. at http://www.mybestpicksever.com
Disclaimer
MyBestPicksEver.Com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. All information provided on this website pertaining to investing, stocks, securities must be understood as information provided and not investment advice.
PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices. PWRM’s stock touched the day high of $0.029 with overall traded volume of 3.12 million shares in the last trading day. It last traded at $0.03 with the no change from its previous close. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease.
PWRM’s products analyze proteins and their mutations to assess an individuals risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. Recently, Power 3 Medical Products Inc. announced that it has filed two provisional patent applications with the United States Patent and Trademark Office.
(USPTO) – one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
These two provisional patent applications, along with the additional provisional patent application recently filed by the principals of Power3 and others on the use of stem cell protein biomarkers to monitor stem cell therapy and three other recently filed provisional patent applications on Parkinson’s and Alzheimer’s disease diagnosis, disclose a vast amount of invaluable information crucial to the accurate diagnosis and treatment of neurodegenerative diseases.
PWRM focuses on the development of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases, such as amytrophic lateral sclerosis (ALS) (also known as Lou Gehrig’s disease), Alzheimer’s disease and Parkinson’s disease.
PWRM addresses clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with academic and research institutions. Power3 applies its methodologies to discover and identify protein biomarkers associated with diseases. It has developed a portfolio of products, including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer, and NuroPro, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases.
Moreover, Power3 Medical Products Inc. plans to make acquisitions. The company is looking at several potential acquisition targets in order to increase its intellectual property portfolio. The company is eyeing acquisition opportunities that could bring promising stem cell research, patents and other intellectual property assets and technologies to help its in-house product development program.
President and Chief Scientific Officer of the company, Ira Goldknopf stated that it will continue to look for acquisitions which could increase shareholder value so stay connected to know more.
Happy trading,
http://www.mybestpicksever.com
MyBestPicksEver offers stock newsletters on various stock plays of the day. MBPE offers news on top stocks, small cap penny stocks and other market movers alike. MBPE help investors in making the wise stock market investments. thus far thousands of our subscribers made huge gains using our daily penny stock alerts. join our FREE news letter Now Or Become a VIP MEMBER.. at http://www.mybestpicksever.com
Disclaimer
MyBestPicksEver.Com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. All information provided on this website pertaining to investing, stocks, securities must be understood as information provided and not investment advice.
Contact Information:
MyBestPicksEver
Chris Wick
Tel: 905-581-5778
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
MyBestPicksEver
Chris Wick
Tel: 905-581-5778
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |